|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
9 January 2023 |
|
Main ID: |
NCT00930423 |
|
Date of registration:
|
29/06/2009 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease
|
|
Scientific title:
|
Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease. |
|
Date of first enrolment:
|
August 2009 |
|
Target sample size:
|
25 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT00930423 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Belgium
| | | | | | | |
|
Contacts
|
|
Name:
|
Raymond Vanholder, MD, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University Hospital, Ghent |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- cases: endstage renal failure due to atypical hemolytic uraemic syndrome treated with
hemodialysis.
- controls: endstage renal failure due to a non complement consuming nephropathy treated
with hemodialysis.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Atypical Hemolytic Uraemic Syndrome
|
|
Primary Outcome(s)
|
|
white blood cell count
[Time Frame: before and after 15 minutes of hemodialysis]
|
|
C3a-des-Arg measuring (as a marker of activation).
[Time Frame: at time 0, at 15 minutes, at 60 minutes and at 180 minutes]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|